-
July 28, 2021
Latest Advances in the Management of Classical Hodgkin Lymphoma: The Era of Novel Therapies Bookmark
George Lundberg, MDThis academic review paper from Blood Cancer Journal outlines many recent advances in the treatment of Hodgkin lymphoma, including for the 15-30% of patients who do not respond or relapse after conventional treatment.
.
-
July 28, 2021
New Approvals for Liver Cancer Mark ‘Golden Age’ of Treatment Bookmark
George Lundberg, MDReported in Healio: After decades of little or no progress, many new clinical trials testing targeted and immunotherapy drugs—especially in combinations—are showing that they have real value in treating primary liver cancer (hepatocellular carcinoma).
.
-
July 28, 2021
Oncolytic Virus Teserpaturev Approved in Japan for Malignant Glioma Bookmark
George Lundberg, MDOncolytic viruses may offer serious hope as a very new type of treatment for malignant glioma. As reported by OncLive, the oncolytic virus teserpaturev was recently approved in Japan after a phase 2 clinical trial.
.
.
-
July 28, 2021
2021 ASCO Annual Meeting Bookmark
George Lundberg, MDResearchers at the 2021 annual meeting of the American Society of Clinical Oncology (ASCO) reported substantial advances in treatment for advanced esophageal, castration-resistant prostate, and metastatic nasopharyngeal cancers.
.
-
July 28, 2021
FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy Bookmark
George Lundberg, MDOn May 28, 2021, the U.S. Food and Drug Administration granted Accelerated Approval for Lumakras (sotorasib), the first targeted therapy for cancer with a mutation in the KRAS gene.
.
-
July 28, 2021
Advances in Colorectal Cancer Research Bookmark
George Lundberg, MDThis outline from the National Cancer Institute covers recent research on colorectal cancer.
.
-
July 14, 2021
What’s New in Melanoma Treatment in 2021?
Emma Shtivelman, PhDI last wrote about melanoma treatment more than 2 years ago, a fairly long time in the evolution of treatments for this type of cancer. Just as a refresher, the current mainstays of drugs to treat melanoma fall into two categories: Immune checkpoint inhibitors (ICI), antibody drugs that bind to proteins found on the immune system’s T cells—namely, PD-1 (which is targeted by the… Read more »
-
June 12, 2021
NALIRIFOX Shows Promise in Early Studies Bookmark
Lola Rahib, PhDArticle from Let’s Win! Pancreatic Cancer: NALIRIFOX, a combination of liposomal irinotecan (Onivyde) with fluorouracil (5-FU), leucovorin, and oxaliplatin is shown to be safe as a first line treatment in locally advanced or metastatic pancreatic cancer.
.
-
June 12, 2021
Multi-Site Precision Promise Study Opens Bookmark
Lola Rahib, PhDArticle from Let’s Win! Pancreatic Cancer: Learn about Precision Promise, an adaptive multi-site clinical trial spearheaded by the Pancreatic Cancer Action Network.
.
-
June 12, 2021
New Trial to Find Biomarkers to Guide Treatment Bookmark
Lola Rahib, PhDArticle from Let’s Win! Pancreatic Cancer: A new clinical trial is using precision medicine to identify the best individualized standard-of-care options for pancreatic cancer patients.
.